Relugolix

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 237 publications

Immediate volume reduction following transvaginal ultrasound-guided thermal ablation (interstitial myolysis) of a symptomatic uterine fibroid.

Immediate volume reduction following transvaginal ultrasound-guided thermal ablation (interstitial myolysis) of a symptomatic uterine fibroid.

Journal: Facts, views & vision in ObGyn
Published: June 22, 2026

Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial.

Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial.

Journal: BMJ open
Published: April 24, 2026

Cerebral Venous Sinus Thrombosis Occurring During Estetrol/Drospirenone Combined Oral Contraceptive Use in a Woman With Multiple Thrombotic Risk Factors: A Case Report.

Cerebral Venous Sinus Thrombosis Occurring During Estetrol/Drospirenone Combined Oral Contraceptive Use in a Woman With Multiple Thrombotic Risk Factors: A Case Report.

Journal: The journal of obstetrics and gynaecology research
Published: April 21, 2026

Relugolix combination therapy in symptomatic adenomyosis and uterine fibroids: a case series.

Relugolix combination therapy in symptomatic adenomyosis and uterine fibroids: a case series.

Journal: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
Published: April 18, 2026

Relugolix : the first oral GnRH receptor antagonist for the treatment of advanced hormone-sensitive prostate cancer

Relugolix : the first oral GnRH receptor antagonist for the treatment of advanced hormone-sensitive prostate cancer

Journal: Revue medicale de Liege
Published: April 16, 2026

New perspectives in managing chronic pelvic pain in endometriosis: the role of GnRH antagonists versus dienogest.

New perspectives in managing chronic pelvic pain in endometriosis: the role of GnRH antagonists versus dienogest.

Journal: Expert opinion on pharmacotherapy
Published: April 10, 2026

Posterior Reversible Encephalopathy Syndrome and Reversible Cerebral Vasoconstriction Syndrome Associated With Relugolix Therapy for Giant Uterine Fibroids and Anemia: A Case Report.

Posterior Reversible Encephalopathy Syndrome and Reversible Cerebral Vasoconstriction Syndrome Associated With Relugolix Therapy for Giant Uterine Fibroids and Anemia: A Case Report.

Journal: Cureus
Published: March 30, 2026

Comparative preclinical assessment of relugolix tablets and relugolix intravenous injection.

Comparative preclinical assessment of relugolix tablets and relugolix intravenous injection.

Journal: Scientific reports
Published: March 25, 2026

Staged Minimally Invasive Management of Prolapsed Submucosal Myoma With Severe Bleeding: A Case Report of Uterine Artery Embolization, Relugolix Therapy, and Transcervical Resection.

Staged Minimally Invasive Management of Prolapsed Submucosal Myoma With Severe Bleeding: A Case Report of Uterine Artery Embolization, Relugolix Therapy, and Transcervical Resection.

Journal: Cureus
Published: March 25, 2026

Letter: Adherence and Persistence on Relugolix for the Treatment of Prostate Cancer in the United States Medicare Fee-for-Service Population.

Letter: Adherence and Persistence on Relugolix for the Treatment of Prostate Cancer in the United States Medicare Fee-for-Service Population.

Journal: Urology practice
Published: February 23, 2026

Bioequivalence of a Fixed-Dose Combination of Relugolix, Estradiol, and Norethindrone Acetate: An Open-Label, Randomized, Fully Replicate Crossover Study in Healthy Postmenopausal Women Under Fasting Conditions.

Bioequivalence of a Fixed-Dose Combination of Relugolix, Estradiol, and Norethindrone Acetate: An Open-Label, Randomized, Fully Replicate Crossover Study in Healthy Postmenopausal Women Under Fasting Conditions.

Journal: Clinical pharmacology in drug development
Published: February 23, 2026

Timing and Resolution of Bothersome Hot Flashes Following Short Course Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix, and Stereotactic Body Radiotherapy for Localized Prostate Cancer.

Timing and Resolution of Bothersome Hot Flashes Following Short Course Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix, and Stereotactic Body Radiotherapy for Localized Prostate Cancer.

Journal: Cureus
Published: February 22, 2026
Showing 1-12 of 237

Last Updated: 06/30/2026